1,946 Shares in Danaher Co. (NYSE:DHR) Bought by Revolve Wealth Partners LLC

Revolve Wealth Partners LLC purchased a new position in shares of Danaher Co. (NYSE:DHR - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,946 shares of the conglomerate's stock, valued at approximately $541,000.

A number of other institutional investors have also recently bought and sold shares of DHR. RFG Advisory LLC boosted its holdings in shares of Danaher by 2.2% during the 1st quarter. RFG Advisory LLC now owns 6,555 shares of the conglomerate's stock worth $1,637,000 after buying an additional 142 shares during the period. True North Advisors LLC grew its position in shares of Danaher by 10.9% in the first quarter. True North Advisors LLC now owns 1,036 shares of the conglomerate's stock valued at $259,000 after purchasing an additional 102 shares during the last quarter. Northwest Investment Counselors LLC bought a new position in shares of Danaher during the first quarter worth approximately $193,000. AdvisorNet Financial Inc increased its stake in shares of Danaher by 11.3% during the first quarter. AdvisorNet Financial Inc now owns 758 shares of the conglomerate's stock worth $189,000 after purchasing an additional 77 shares during the period. Finally, Global Assets Advisory LLC bought a new stake in Danaher in the 1st quarter valued at $40,656,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Buying and Selling at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the company's stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company's stock, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company's stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have weighed in on DHR shares. Stephens initiated coverage on Danaher in a research report on Tuesday, October 1st. They set an "overweight" rating and a $315.00 price objective on the stock. Barclays lifted their price objective on shares of Danaher from $270.00 to $285.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 24th. Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Robert W. Baird lifted their price target on shares of Danaher from $271.00 to $278.00 and gave the company an "outperform" rating in a research report on Wednesday, July 24th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $282.12.

Danaher Price Performance

Shares of DHR stock traded up $2.40 on Friday, reaching $274.38. The company had a trading volume of 1,949,849 shares, compared to its average volume of 2,717,951. The stock has a market capitalization of $203.23 billion, a PE ratio of 46.51, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The business's 50-day moving average is $270.72 and its 200 day moving average is $260.13. Danaher Co. has a one year low of $182.09 and a one year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts' consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business posted $2.05 earnings per share. The company's quarterly revenue was down 2.9% on a year-over-year basis. Equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. Danaher's payout ratio is presently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.